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Abstract	Hepatitis	C	virus	rapidly	evolves,	conferring	resistance	to	direct	acting	antivirals.	While	resistance	via	active	site	mutations	in	the	viral	NS3/4A	protease	has	been	well	characterized,	the	mechanism	for	resistance	of	non-active	site	mutations	is	unclear.	R155K	and	V36M	often	co-evolve	and	while	R155K	alters	the	electrostatic	network	at	the	binding	site,	V36M	is	more	than	13	Å	away.	In	this	study	the	mechanism	by	which	V36M	confers	resistance,	in	the	context	of	R155K,	is	elucidated	with	drug	susceptibility	assays,	crystal	structures,	and	molecular	dynamics	(MD)	simulations	for	three	protease	inhibitors:		telaprevir,	boceprevir	and	danoprevir.	The	R155K	and	R155K/V36M	crystal	structures	differ	in	the	α-2	helix	and	E2	strand	near	the	active	site,	with	alternative	conformations	at	M36	and	side	chains	of	active	site	residues	D168	and	R123,	revealing	an	allosteric	coupling,	which	persists	dynamically	in	MD	simulations,	between	the	distal	mutation	and	the	active	site.	This	allosteric	modulation	validates	the	network	hypothesis	and	elucidates	how	distal	mutations	confer	resistance	through	propagation	of	conformational	changes	to	the	active	site.				
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Introduction		Hepatitis	C	(HCV)	infection	causes	inflammation	of	the	liver	and	can	lead	to	cirrhosis	and	liver	cancer	if	not	treated	effectively.	HCV	NS3/4A	protease	inhibitors	(PIs)	were	the	first	class	of	direct-acting	anti-virals	(DAAs)	approved	by	the	FDA	to	be	used	in	combination	with	peginterferon-alfa	and	ribavirin.	These	PIs	included	the	covalent,	acyclic	inhibitors	(telaprevir	(Perni,	Almquist	et	al.	2006,	Kwong,	Kauffman	et	al.	2011),	boceprevir	(Malcolm,	Liu	et	al.	2006))	and	a	non-covalent,	macrocyclic	inhibitor	(simeprevir	(Raboisson,	de	Kock	et	al.	2008,	Rosenquist,	Samuelsson	et	al.	2014).	Subsequently,	macrocyclic	PIs	have	been	developed	as	second-generation	DAAs,	including	danoprevir,	grazoprevir,	and	recently	FDA-approved	glecaprevir.			PIs	target	the	virally	encoded	serine	protease	NS3/4A.	NS3	is	a	631	amino-acid	bifunctional	protein,	with	a	serine	protease	domain	in	the	N-terminus	followed	by	an	NTPase/RNA	helicase	domain.	The	crosstalk	between	the	two	domains	has	been	previously	reported	(Frick,	Rypma	et	al.	2004,	Beran	and	Pyle	2008,	Beran,	Lindenbach	et	al.	2009,	Aydin,	Mukherjee	et	al.	2013),	but	domains	fold	into	active	proteins	independently.	NS3/4A	protease	domain,	a	chymotrypsin-like	fold	with	two	β-barrel	domains,	has	a	catalytic	triad	(H57,	D81,	S139)	located	in	a	cleft	separating	the	two	barrels.	NS4A,	a	54-amino	acid	peptide,	is	required	as	a	cofactor	for	optimal	proteolytic	activity.	The	central	11	amino	acids	of	the	cofactor	inserts	as	a	β-strand	to	the	N-terminal	β-barrel	of	NS3	to	form	the	active	enzyme	(Yao,	Reichert	et	al.	1999).			
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While	PIs	offer	a	subpopulation	of	patients	improved	sustained	virologic	response	and	the	potential	for	shorter	therapy	duration	(Jacobson,	McHutchison	et	al.	2011,	Poordad,	McCone	et	al.	2011,	Sherman,	Flamm	et	al.	2011,	Gane,	Pockros	et	al.	2012),	the	efficacy	of	approved	PIs	is	challenged	by	drug	resistance	(Halfon	and	Locarnini	2011,	Halfon	and	Sarrazin	2012,	Svarovskaia,	Martin	et	al.	2012,	Vermehren	and	Sarrazin	2012,	Welsch	and	Zeuzem	2012).	Mutations	arise	in	the	NS3/4A	protease	depending	on	the	therapeutic	regime;	A156	mutates	in	response	to	treatment	with	linear	ketoamide	protease	inhibitors	(Kieffer,	Sarrazin	et	al.	2007,	Sarrazin,	Kieffer	et	al.	2007,	Susser,	Welsch	et	al.	2009,	Halfon	and	Sarrazin	2012,	Svarovskaia,	Martin	et	al.	2012,	Vermehren	and	Sarrazin	2012,	Welsch	and	Zeuzem	2012)	while	macrocyclic	PIs	mainly	select	for	D168A	and	R155K	variants	(Manns,	Reesink	et	al.	2011,	Manns,	Bourliere	et	al.	2011,	Lim,	Qin	et	al.	2012).	Mutations	at	V36,	T54,	V36/R155	were	initially	reported	to	be	associated	with	resistance	to	ketoamide	inhibitors	(Kieffer,	Sarrazin	et	al.	2007,	Sarrazin,	Kieffer	et	al.	2007,	Susser,	Welsch	et	al.	2009).	V36M/R155K	mutations	were	observed	in	long-term	follow-up	of	patients	receiving	boceprevir	(Howe,	Long	et	al.	2015).	An	interferon-free	mericitabine/danoprevir	combination	therapy	resulted	in	a	confirmed	viral	breakthrough	in	21%	of	patients	(Gane,	Pockros	et	al.	2012)	and	these	patients	had	danoprevir-resistant	variants,	including	V36M/R155K.	Although	the	newer	PIs	have	improved	potency	and	cure	rates	in	combination	therapy,	dual	and	triple	mutant	variants	including	those	with	V36M	mutations	still	emerge	in	patients	failing	therapy	(Sorbo,	Cento	et	al.	2018)			We	have	previously	elucidated	the	structural	basis	of	resistance	due	to	the	active	site	mutation	R155K	by	crystal	structures	(Romano,	Ali	et	al.	2010,	Romano,	Ali	et	al.	2012).	
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R155	participates	in	an	electrostatic	network	of	interactions	along	the	substrate-binding	surface,	which	involves	residues	D81-R155-D168-R123.	This	strong	electrostatic	network	is	associated	with	tighter	substrate	binding	(Romano,	Laine	et	al.	2011),	therefore	is	critical	in	stabilization	of	the	bound	ligands.	In	fact,	most	early	inhibitors,	particularly	the	compounds	with	aromatic	P2	moieties,	pack	against	R155.	Our	crystal	structures	(Romano,	Ali	et	al.	2010,	Romano,	Ali	et	al.	2012,	Soumana,	Ali	et	al.	2014)	showed	that	the	R155K	mutation	disrupts	this	network	by	eliminating	one	of	the	two	hydrogen	bonds	of	R155.	As	a	result,	the	altered	charge	distribution	along	the	binding	surface	affects	the	P2	cyclopentylproline	and	P4	cyclohexylalanine	moieties	of	telaprevir	whereas	danoprevir	loses	a	favorable	cation-π	interaction	at	the	P2	isoindoline	(Romano,	Ali	et	al.	2012).	MD	simulations	based	on	these	crystal	structures	suggest	that	the	destruction	of	the	salt	bridge	between	168	and	155	may	cause	additional	conformational	changes	in	the	binding	pocket	(Pan,	Xue	et	al.	2012).		Unlike	R155K,	the	molecular	mechanism	of	resistance	for	V36M	mutation	is	unknown.	V36M	is	a	mutation	distal	to	the	active	site,	located	on	A1	strand,	>	13	Å	away	from	the	catalytic	histidine	(H57)	and	15	Å	from	R155	(Figure	1).	In	the	absence	of	crystal	structures,	molecular	modeling	led	to	the	hypothesis	that	the	distal	mutations	at	V36	and	T54	can	impair	interaction	with	telaprevir’s	cyclopropyl	group	(Welsch,	Domingues	et	al.	2008).	However,	no	experimental	data	exists	on	the	structural	changes	due	to	V36M	and	how	the	effects	of	this	distal	mutation	may	affect	PI	binding	at	the	active	site.	We	have	previously	developed	the	“network	hypothesis”	postulating	that	the	effect	of	distal	mutations	in	HIV-1	protease	are	propagated	to	the	active	site	through	a	network	of	intra-
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molecular	interactions	to	confer	drug	resistance	(Ragland,	Nalivaika	et	al.	2014).	The	network	hypothesis	may	be	applicable	to	distal	mutations	in	HCV	NS3/4A	protease	as	well,	if	this	is	a	general	mechanism	by	which	resistance	occurs.		To	understand	why	the	distal	mutation	V36M	is	selected	together	with	the	active	site	mutation	R155K	to	confer	drug	resistance,	we	determined	the	crystal	structures	of	R155K/V36M	double	mutant	HIV	NS3/4A	protease	with	three	PIs:	telaprevir,	boceprevir,	and	danoprevir	(Table	S1).	Through	a	combination	of	drug	susceptibility	assays	(enzymatic	and	viral	replicon),	extensive	structural	analysis	and	MD	simulations,	we	show	that	V36M	accentuates	resistance	to	PIs	by	allosterically	modulating	the	conformation	and	dynamics	of	the	active	site.	Most	notably,	the	change	in	the	shape	of	the	binding	site	in	NS3/4A	protease	is	induced	through	a	conformational	shift	in	B1	strand.	These	findings	provide	key	insights	into	the	interplay	between	the	structural	and	mutational	plasticity	of	the	enzyme	in	conferring	drug	resistance;	validating	the	network	hypothesis	(Ragland,	Nalivaika	et	al.	2014)	and	explaining	how	distal	mutations	are	able	to	contribute	to	conferring	drug	resistance	through	alteration	of	the	dynamic	network	and	modulation	of	the	active	conformations.			
Results	
	To	understand	the	molecular	basis	of	the	selection	of	V36M	distal	mutation	under	the	pressure	of	PI	including	regimens,	wild-type	(WT)	and	resistant	protease	variants	carrying	R155K	and	R155K/V36M	mutations	were	compared	for	binding	telaprevir,	boceprevir,	and	danoprevir.	Crystal	structures	of	the	R155K/V36M	double	mutant	protease	were	
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determined	in	complex	with	the	three	PIs	(Table	S1),	and	analyzed	in	comparison	with	our	previously	published	crystal	structures	of	the	telaprevir-	and	danoprevir-bound	R155K	single	mutant	(Romano,	Ali	et	al.	2012).		For	additional	comparison,	high-resolution	crystal	structures	of	apo	and	boceprevir-bound	WT	were	also	determined	(Table	S1)	and	carefully	generated	models	of	apo	R155K	and	R155K/V36M	variants	(see	Materials	and	Methods).	These	twelve	(10	crystal	and	2	model)	resulting	structures	and	their	subsequent	MD	simulations	(100	ns	in	triplicate)	were	analyzed	for	changes	in	protein	structure,	dynamics,	and	molecular	interactions	at	the	binding	site.	In	addition,	the	susceptibility	of	the	single	and	double	mutant	variants	to	the	three	PIs	was	determined	both	with	enzymatic	and	viral	assays.		
V36M	Further	Decreases	Susceptibility	of	R155K	variants	to	PIs		The	activity	of	the	three	PIs	against	R155	and	R155/V36M	variants	was	assessed	by	enzymatic	(Ki)	and	the	cellular	half-maximal	(IC50)	inhibition	constants	(Table	1).	The	enzyme	inhibition	constant	against	the	full-length	NS3/4A	versus	the	protease	domain	alone	was	comparable,	regardless	of	the	PI	or	mutation	introduced,	suggesting	a	minimal	role	for	the	helicase	domain	in	protease	inhibitor	binding.	All	three	PIs	are	significantly	less	active	against	the	double	mutant	than	against	the	WT	and	R155K	variants.	Compared	to	WT	enzyme,	boceprevir	has	7-	and	31-fold	less	inhibitory	activity	against	the	R155K	and	R155K/V36M	protease	respectively	(Table	1)	while	telaprevir	loses	even	more	activity,	24-fold	against	R155K	and	more	than	200-fold	against	R155K/V36M.	For	danoprevir,	the	fold-reduction	in	Ki	relative	to	WT	is	remarkably	severe	for	both	single	and	double	mutants,	158-fold	and	295-fold	respectively.	Despite	this	severe	fold-change	in	potency,	danoprevir	
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is	still	the	most	potent	among	the	three	PIs	against	the	resistant	protease	variants,	due	to	an	order-of-magnitude	better	potency	against	WT	protease	(1.2	nM	versus	34.7	and	40.9	nM).		While	the	double	mutant	has	varying	degrees	of	susceptibility	to	the	three	PIs,	in	all	cases,	V36M	enhances	resistance	against	both	linear	and	macrocyclic	compounds	compared	to	R155K	alone.			Replicon-based	cellular	inhibition	results	correlate	well	with	the	enzyme	inhibition	constants.	For	all	three	PIs,	the	loss	of	antiviral	activity	(fold-change	in	IC50	relative	to	wild-type)	against	the	R155K/V36M	clones	is	substantial	compared	to	the	HCV	clones	carrying	the	R155K	single	mutation.	In	replicon	assays,	telaprevir	and	boceprevir	lost	more	than	3-fold	activity	with	R155K	mutation	while	these	linear	compounds	were	12-	and	4-fold	less	potent	against	the	R155K/V36M	virus	relative	to	wild-type.	The	IC50	of	danoprevir	was	beyond	the	100	nM	assays	limit,	which	corresponds	to	more	than	416-fold	loss	of	antiviral	activity.	In	conclusion,	the	non-active	site	mutation	V36M	reduces	the	activity	of	all	three	PIs	both	on	molecular	and	cellular	levels	in	the	presence	of	the	active	site	mutation	R155K.			
R155K/V36M	Mutations	Destabilize	Danoprevir’s	Large	P2	Moiety	The	overall	binding	modes	of	PIs	were	conserved	regardless	of	the	resistance	mutations	in	the	crystal	structures	(Figure	2).	However,	protease–inhibitor	interactions	were	altered	due	to	the	mutations	to	varying	extends.	Danoprevir	exhibits	the	largest	shift	due	to	the	resistance	mutations	in	the	crystal	structures.	P2-isoindoline	of	danoprevir	is	in	direct	contact	with	the	site	of	mutation,	forming	cation-π	stacking	interactions	with	R155,	while	
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the	P2	groups	of	telaprevir	and	boceprevir	are	smaller	and	relatively	distant	to	the	155	sidechain.	The	R155K	mutation	disrupts	the	favorable	cation-π	stacking	and	causes	a	shift	in	the	danoprevir	P2	moiety	in	the	crystal	structures	of	both	the	single	and	double	mutant	complexes	(Figure	2	and	3A).	These	changes	have	been	described	as	the	mechanism	underlying	resistance	of	R155K	protease	to	danoprevir	(Romano,	Ali	et	al.	2012).	In	addition	to	these	structural	changes,	our	MD	simulations	here	reveal	that	the	interactions	of	danoprevir’s	P2	moiety	with	the	protease	are	destabilized	in	both	protease	variants,	with	a	considerably	enhanced	conformational	flexibility	of	the	bound	inhibitor	(Figure	3B).	This	enhanced	conformational	flexibility	causes	loss	of	favorable	interactions	even	more	than	those	observed	in	the	crystal	structures,	including	with	the	catalytic	residues	D81	and	H57	(Figure	4	versus	S1).	The	P2	moiety	samples	alternate	conformations	different	than	that	in	the	starting	crystal	structure	or	the	WT	complex	during	the	simulations	and	loses	more	than	6	kcal/mol	in	van	der	Waals	interactions	with	the	protease,	mainly	with	residues	155–157	(Figure	5).	In	both	single	and	double	mutant	variants,	danoprevir	also	loses	favorable	packing	of	the	P1'	moiety	with	F43	on	the	B1	strand	(Figure	5),	which	interfaces	both	the	active	site	and	A1	strand	containing	the	site	of	distal	mutation.	In	the	R155K/V36M	protease	complex,	danoprevir	forms	new	interactions	with	V158,	S159,	and	T160	not	present	in	WT	and	R155K	variants	(Figure	5).	Previously	we	found	these	residues	form	more	favorable	interactions	with	the	substrates	than	inhibitors	(Ozen,	Sherman	et	al.	2013).		Thus,	while	the	loss	of	van	der	Waals	interactions	in	the	danoprevir	crystal	structures	are	less	pronounced	and	comparable	for	the	single	and	double	mutant	variants,	the	destabilization	and	further	loss	of	P2	interactions	revealed	in	MD	simulations	correlate	with	the	high	fold-change	in	potency	(Table	1).	
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R155K/V36M	Mutations	Impact	Dynamic	Packing	of	Linear	Inhibitors	at	the	Active	Site		The	two	linear	inhibitors	with	smaller	P2	moieties,	telaprevir	and	boceprevir,	have	comparable	potencies	against	WT	protease,	but	telaprevir	is	more	susceptible	to	resistance	due	to	the	R155K	and	V36M	mutations	(Table	1).	The	loss	of	vdW	interactions	with	the	mutation	site	in	R155K	variants	is	much	less	pronounced	in	the	two	linear	inhibitors	compared	to	danoprevir,	in	both	crystal	structures	and	MD	simulations	(less	than	1	kcal/mol,	Figures	4	and	S1),	likely	due	to	lack	of	a	large	P2	moiety	packing	against	residue	155.		Telaprevir	loses	favorable	vdW	interactions	mainly	with	residue	155	and	the	catalytic	H57	at	its	P2	and	P4	positions,	while	boceprevir	loses	interactions	also	with	K136,	A156	and	A157	(Figure	4).			In	the	crystal	structures,	the	distal	site	mutation	V36M	causes	further	loss	of	vdW	contacts	with	K136	and	R155	for	telaprevir	and	boceprevir,	respectively	(Figure	S1),	compared	to	R155K	alone.	However,	comparison	of	the	vdW	energies	in	the	crystal	structures	versus	dynamic	conformations	sampled	during	MD	indicates	that	the	V36M	distal	mutation	significantly	alters	the	dynamic	interactions	between	the	inhibitors	and	the	protease	(Figures	4	and	S1).	Unlike	in	the	crystal	structures,	the	overall	impact	of	resistance	mutations	is	not	localized	to	a	single	residue	but	dispersed	through	subtle	changes	in	the	vdW	contacts	over	the	binding	surface	altering	the	packing	of	inhibitors	to	the	resistant	variant	proteases.		
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Key	protease	residue	side	chains	in	contact	with	telaprevir	are	perturbed	by	the	R155K/V36M	double	mutation.	The	telaprevir-bound	R155K/V36M	protease	crystal	structure	has	multiple	side	chain	conformations	at	the	M36	position.	Substitution	of	a	valine	at	a	relatively	buried	position	to	a	larger	methionine	side	chain	alters	the	local	packing,	and	the	M36	side	chain	assumes	these	alternate	conformations.	This	perturbation	of	side	chain	packing	due	to	V36M	mutation	is	transmitted	to	the	protease	active	site	causing	two	residues,	D168	and	R123,	which	are	part	of	the	active	site	electrostatic	network,	to	have	alternate	conformations	as	well.	Hence,	in	the	double	mutant,	the	active	site	electrostatic	network	is	destabilized	both	due	to	active	site	R155K	and	the	distal	V36M	mutations	(Table	2).	In	addition,	K136,	which	plays	a	role	in	substrate	recognition	through	favorable	electrostatic	interactions	with	the	acidic	P6	position	in	the	substrates,	also	makes	favorable	vdW	contacts	with	telaprevir.	However,	no	clear	density	was	observed	for	the	K136	sidechain	in	R155K/V36M	co-crystal	structure	of	telaprevir,	suggesting	that	the	distal	V36M	mutation	has	perturbed	the	interactions	of	K136	in	α1	helix	with	telaprevir.	Dramatic	loss	of	affinity	with	R155K/V36M	compared	to	the	single	mutant	R155K	may	be	partially	due	to	these	conformational	changes	observed	in	the	crystal	structures	both	in	the	binding	site	and	at	the	distal	site	of	mutation.			
Resistance	Mutations	Cause	Changes	in	the	Active	Site	Electrostatic	Network		Hydrogen	bonds	are	significant	contributors	to	inhibitor	binding.	The	PIs	make	hydrogen	bonds	mainly	with	the	backbone	donors/acceptors	in	the	binding	site	(Figure	6).	As	a	result,	the	impact	of	R155K	on	the	hydrogen-bonding	network	is	minimal.	Distance	between	the	hydrogen	bond	donor	and	acceptor	atoms	vary	0.2	Å	at	most,	staying	the	same	
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for	the	most	part	in	crystal	structures.	However	in	MD	simulations,	because	of	the	structural	rearrangement	in	the	binding	site	caused	by	V36M,	the	likelihood	of	a	hydrogen	bond	with	the	backbone	oxygen	decreases	~20%	for	telaprevir	and		~10%	for	boceprevir	(Table	S2).	The	most	striking	difference	between	the	crystal	structures	and	MD	simulations	is	that	both	telaprevir	and	danoprevir	lose	a	hydrogen	bond	with	the	catalytic	H57,	which	is	observed	~60%	of	the	time	between	boceprevir	and	WT	or	R155K	protease,	but	drops	to	34%	in	R155K/V36M	complex.	In	contrast,	hydrogen	bonds	with	R/K155	and	A157	(on	the	E2	strand)	are	preserved	in	the	MD	simulations,	suggesting	that	these	bonds	are	key	contributors	to	inhibitor	binding.	Hence,	drug	resistance	mutations	modulate	the	relative	stability	of	certain	inter-molecular	hydrogen	bonds	in	the	conformational	ensembles	sampled	in	the	MD	simulations	while	the	hydrogen	bonds	that	are	likely	indispensable	for	binding	remain	stable	across	crystal	structures	and	throughout	the	simulations	of	mutant	complexes.			The	electrostatic	network	at	the	binding	site	of	NS3/4A,	involving	residues	H57–R155–D168–R123,	is	important	for	substrate	recognition	and	inhibitor	binding	(Romano,	Laine	et	al.	2011,	Ali,	Aydin	et	al.	2013).	Disruption	of	this	network	can	arise	as	a	mechanism	of	resistance	by	weakening	inhibitor	binding.	Therefore,	sensitivity	of	the	salt	bridges	in	this	network	to	resistance	mutations	was	assessed	(Table	2).	R155	can	make	two	salt	bridges,	one	with	D81	and	the	other	with	D168	in	all	PI-bound	structures.	In	the	wild-type	protease	simulations,	R155–D168	salt	bridge	is	more	stable	than	the	R155–D81	salt	bridge,	consistent	with	the	distances	observed	in	the	crystal	structures	(6.4	Å	for	D81–R155	and	4.8	Å	for	R155–D168).	While	danoprevir	binding	further	stabilizes	R155–D168,	the	linear	
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inhibitors,	telaprevir	and	boceprevir,	optimize	the	electrostatic	network	on	the	binding	surface	such	that	both	the	salt	bridges	exist	more	than	~80%	of	the	time.	However,	R155K	mutation	favors	D81–K155	over	K155–D168	in	telaprevir	and	danoprevir	complexes	but	not	in	boceprevir.	Relative	stability	of	K155–D168	in	boceprevir	complex	is	dependent	on	the	stability	of	the	H57–D81	salt	bridge,	since	D81	is	no	longer	available	for	a	salt	bridge	with	K155.	In	boceprevir-bound	protease,	disruption	of	the	electrostatic	network	along	the	binding	surface	is	predominantly	orchestrated	by	R155K	mutation	as	D81–R/K155	salt	bridge	likelihood	drops	from	85%	in	wild-type	complex	to	less	than	5%	in	both	R155K	and	R155K/V36M	variants.	A	slight	destabilization	of	D81–K155	is	observed	in	the	telaprevir-bound	and	danoprevir-bound	R155K/V36M	proteases	(the	percentages	that	D81–K155	salt	bridge	existed	dropped	from	89%	to	83%	and	from	84%	to	78%,	respectively).	The	last	residue	in	the	network,	R123,	is	solvent	exposed	even	in	the	bound	state;	therefore	the	sidechain	conformation	may	be	sensitive	to	crystal	contacts	also	impacting	the	stability	of	the	other	salt	bridges	in	the	network.	To	test	this	possibility,	all	the	potential	salt	bridges	on	the	protein	surface	were	evaluated	(Table	2).	Neither	inhibitor	binding	nor	mutations	in	the	protease	significantly	changed	the	surface	salt	bridges,	suggesting	that	the	changes	observed	on	the	electrostatic	network	involving	H57–D81–R/K155–D168–R123	is	due	to	the	mutations	in	the	protease	but	not	alternate	conformations	of	R123	favored	in	different	crystals.	Thus,	the	fluctuations	in	the	salt	bridges,	combined	with	the	relative	susceptibilities	of	PIs	to	the	R155K	mutation,	suggest	that	the	electrostatic	network	along	the	binding	site	is	a	key	factor	stabilizing	the	interactions	of	the	bound	inhibitor.			
V36M	Causes	Distal	Perturbations	in	Protease	Backbone	Conformation	and	Flexibility		
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Backbone	structural	changes	in	the	crystal	structures	were	assessed	by	computing	the	differences	in	the	internal	Cα-Cα	distances	between	the	resistant	and	wild-type	variants	bound	to	each	inhibitor	(Figure	7).	This	analysis	enables	determining	the	overall	conformational	perturbation	in	the	protein	structure	due	to	resistance	mutations	without	any	possible	superposition	bias	(see	Materials	and	Methods).			When	the	single	R155K	mutation	is	introduced	to	the	protease,	the	backbone	conformation	is	the	most	affected	in	the	macrocyclic	danprevir-bound	structure.	Introducing	V36M	mutation	to	the	R155K	variant	further	alters	the	backbone	conformation	relative	to	wild-type	complex.	Backbone	of	danoprevir-bound	protease,	which	has	a	~300-fold	reduction	in	inhibitory	activity	due	to	R155K/V36M,	is	altered	more	than	the	backbone	of	linear	telaprevir-	and	boceprevir-bound	protease	with	a	per-residue	average	difference	of	0.14	Å	(for	the	linear	inhibitors:	0.08	Å	for	telaprevir,	0.09	Å	for	boceprevir).	The	V36M	distal	mutation	shifts	the	danoprevir-bound	protease	backbone	both	at	the	binding	site	and	distal	regions	of	the	structure	(Figure	7).	Significant	binding	site	changes	include	the	loop	connecting	the	E2-F2	strands	and	the	α2	helix,	while	subtle	changes	are	observed	at	α1	helix	that	includes	the	catalytic	H57.	Distal	regions	with	substantial	backbone	perturbations	correspond	to	the	loop	connecting	the	β-strands	A1	(residue	36	is	located	on	A1)	and	B1,	the	α0	N-terminal	region,	and	the	α3	C-terminal	region.	Most	of	these	regions	are	also	flexible	and	exhibit	high	fluctuations	in	the	MD	simulations	(see	below	and	Figure	8).	Correspondence	between	the	crystallographic	changes	in	the	distance-difference	maps	and	the	relative	flexibility	in	MD	simulations	suggests	that	the	resistance	mutations	mainly	perturb	the	backbone	conformation	of	relatively	flexible	regions.		
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	In	addition	to	structural	changes	in	the	inhibitor-bound	state,	resistance	mutations	can	affect	the	conformational	dynamics	of	the	bound	and	unbound	states	(Cai,	Yilmaz	et	al.	2012).	Overall,	the	local	backbone	fluctuations	in	apo	versus	inhibitor-bound	complexes	of	wild	type	NS3/4A	protease	are	comparable	(Figure	8).	The	core	of	the	protein	comprised	mostly	of	beta	strands	is	highly	stable	in	all	simulations,	also	supported	by	the	stable	secondary	structures	over	the	trajectories.	Regions	with	changes	in	flexibility	mainly	correspond	to	loops	and	helices	(with	higher	RMSF	values	in	Figure	8).	The	fluctuations	of	the	short	α1	helix,	which	includes	the	catalytic	H57,	were	suppressed	when	telaprevir	or	danoprevir	binds	but	stays	apo-like	with	boceprevir	binding.	Another	region	that	is	in	close	proximity	to	the	binding	site,	corresponding	to	residues	130–137	and	including	helix	α2,	lost	flexibility	when	any	of	the	three	inhibitors	binds	(Figure	8),	consistent	with	earlier	simulation	results	(Zhu	and	Briggs	2011).	In	this	segment	of	NS3/4A,	I132,	L135,	K136,	and	G137	and	to	an	extent	S138	make	favorable	vdW	interactions	with	the	inhibitor	while	the	backbone	amide	of	G137	hydrogen	bonds	to	the	inhibitors.	Interestingly,	allosteric	inhibitors	of	NS2B/NS3	(Yildiz,	Ghosh	et	al.	2013),	another	trypsin-like	serine	protease	from	dengue	virus,	bind	a	region	of	the	enzyme	that	is	topologically	similar	to	the	130–137	segment	of	HCV	NS3/4A.	Structural	ordering	achieved	by	tight,	favorable	interactions	with	the	inhibitor	implies	a	role	of	this	3-10	helix	in	stabilizing	the	active	site.		We	next	analyzed	changes	in	backbone	fluctuations	due	to	resistance	mutations	(Figure	9).	Relatively	restrained	residues	in	the	wild-type	protease,	bound	or	unbound,	are	not	majorly	affected	by	the	resistance	mutations.	The	most	striking	change	in	atomic	
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fluctuations	with	V36M	mutation	is	observed	at	telaprevir-bound	protease’s	A2,	B2,	and	C2	strands,	which	became	significantly	more	restrained	compared	to	the	wild-type	or	R155K	single	mutant.	When	bound	to	danoprevir,	residues	70–80,	which	form	E1	strand,	were	relatively	rigid	in	the	wild-type	protease	and	became	flexible	in	both	R155K	and	R155K/V36M	variants.	In	boceprevir-bound	protease,	this	region	became	flexible	only	in	the	double	mutant	and	not	in	the	single	R155K	mutant.	Overall,	the	resistance	mutations	changed	backbone	flexibility	not	at	or	near	the	site	of	mutation	but	at	other	distal	regions,	and	the	extent	of	this	change	correlated	with	fold-changes	in	inhibitor	affinity	(Figure	9	and	Table	1).		
The	Distal	V36M	Mutation	Changes	the	Active	Site	via	F43	To	better	capture	the	dynamic	changes	at	the	binding	site	due	to	resistance	mutations,	inter-residue	Cα-Cα	distance	during	MD	simulations	was	tracked	for	pairs	of	protease	residues.	The	distance	distribution	does	not	considerably	change	for	most	of	the	residue	pairs	and	fluctuate	around	the	distance	in	crystal	structure	regardless	of	mutations.	However,	V36M	mutation	changed	the	dynamics	and	distance	sampled	for	some	key	residue	pairs	across	and	away	from	the	active	site	(Figures	10	and	S2–S5).	In	the	presence	of	V36M,	residue	36	and	F43	become	closer	to	each	other	compared	to	WT	and	R155K	complexes	(Figure	10A).	F43	interacts	with	the	bound	inhibitor	and	is	located	in	B1	strand,	which	bridges	the	distal	V36M	mutation	on	the	A1	strand	to	the	binding	site	(Figure	1).		We	found	that	four	residues,	K136	in	α2	helix	and	residues	155–157	on	E2	β-strand,	also	became	closer	to	F43	with	V36M	mutation	(Figures	10A	and	S2).	The	fact	that	E2	and	B1	β-
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strands	and	the	α2	helix	are	closer	to	each	other	suggests	a	slight	shrinking	in	the	binding	site	across	the	B1–E2	strands	direction.				Structural	and	dynamic	reorganization	in	the	binding	site	involving	the	α2	helix	and	B1	and	E2	strands	also	impacted	the	catalytic	triad	(Figure	10B).	In	the	apo	protease,	S139	was	pulled	away	from	H57	and	D81	with	the	V36M	mutation.	In	telaprevir	and	danoprevir	complexes,	R155K	mutation	caused	H57	and	D81	Cα	atoms	to	get	farther	away	from	each	other,	which	was	further	aggravated	by	V36M	in	danoprevir-bound	protease.	When	farther	apart,	the	sidechains	of	these	two	catalytic	residues	are	not	oriented	properly	for	strong	salt	bridging	(Table	2).	In	contrast,	the	distances	and	the	H57-D81	salt	bridge	were	conserved	in	complexes	of	boceprevir,	which	is	the	least	susceptible	of	the	three	inhibitors	to	R155K/V36M	resistance	mutations	(Table	1).			Additional	residue	pairs	across	the	protease	indicate	changes	in	the	conformational	dynamics	due	to	the	resistance	mutations.	The	H57-K136	distance	decreased	in	the	unbound	variants	of	R155K	and	R155K/V36M,	with	a	bimodal	distribution	in	R155K/V36M	(Figure	S4).	Since	K136	makes	key	interactions	with	the	natural	substrates,	one	would	expect	that	a	change	in	the	relative	orientation	of	K136	with	respect	to	the	catalytic	H57	could	alter	the	balance	in	the	molecular	recognition	events	in	favor	of	substrate	recognition	versus	inhibitor	binding.	The	loops	connecting	A1-B1	and	E2-F2	strands,	which	can	be	thought	of	as	“pseudo-flaps”	in	analogy	to	HIV-1	protease,	were	also	closer	to	each	other	in	the	apo	and	danoprevir-bound	proteases	while	the	width	of	the	distribution	changed	in	telaprevir-bound	state	(Figure	S3).	
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	Since	the	A1	strand,	where	V36	is	located,	is	in	direct	contact	with	the	NS4A	cofactor	in	structure	(Figure	1),	a	mutation	in	A1	may	also	affect	the	interactions	with	NS4A.	To	assess	whether	the	V36M	mutation	interferes	with	the	binding	of	the	cofactor	NS4A,	which	aids	in	the	proper	folding	of	NS3,	we	calculated	the	distance	distributions	between	the	cofactor	and	NS3	residues	as	well.	Overall,	there	were	no	considerable	changes	except	for	subtle	shifts	in	the	distance	between	residues	V/M36	in	A1	and	R28	in	NS4A	in	the	apo	protease,	and	biomodal	distance	distribution	between	E13	and	I25	in	the	inhibitor-bound	complexes	(Figure	S5).			In	summary,	detailed	investigation	of	co-crystal	structures	and	conformational	ensembles	coupled	with	drug	susceptibility	assays	show	that	the	distal	site	mutation	V36M,	in	the	presence	of	the	binding	site	mutation	R155K,	alters	the	binding	site	shape	through	changes	in	conformational	dynamics.				
Discussion	and	Conclusions	Molecular	basis	of	drug	resistance	in	HCV	NS3/4A	protease	conferred	by	V36M	in	the	R155K	background	has	been	investigated	using	a	combination	of	drug	susceptibility	assays,	co-crystal	structures,	and	MD	simulations.	Binding	assays	and	replicon	studies	were	consistent	in	showing	that	the	R155K/V36M	double	mutant	is	more	resistant	to	telaprevir,	boceprevir,	and	danoprevir	than	the	single	mutant	R155K	(Table	1).	The	linear	inhibitors	are	more	susceptible	to	the	V36M	distal	mutation	in	the	presence	of	R155K	than	the	
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macrocyclic	danoprevir;	the	fold-change	in	Ki	due	to	V36M	was	9	and	4	for	telaprevir	and	boceprevir,	respectively	and	2	for	danoprevir	in	the	R155K	background.	However,	as	danoprevir	is	highly	susceptible	to	R155K	(158-fold	change	relative	to	WT),	the	double	mutant	had	almost	300	times	higher	inhibition	constant	than	the	WT	protease.		Why	the	V36M	mutation	distal	from	the	active	site	is	selected	in	combination	with	R155K	and	how	this	mutation	is	able	to	impact	inhibitor	susceptibility	is	not	entirely	evident	from	the	crystal	structures	alone.	The	impact	of	the	distal	V36M	mutation	on	the	crystal	structures	is	subtle,	with	little	change	in	the	inhibitor	binding	mode,	intermolecular	hydrogen	bonds	or	salt	bridges.	However,	rather	than	local	changes	at	the	binding	site,	V36M	alters	the	overall	protein	conformation	and	dynamics	around	the	active	site	via	changes	in	interactions	with	F43	on	B1	strand	(Figures	7,	10	and	S2).	Our	results	suggest	that	the	impact	of	V36M	mutation	is	propagated	to	the	binding	site	through	B1	β-strand	since	V36	is	located	on	the	A1	β-strand,	right	next	to	B1	strand.	The	fact	that	F43,	on	B1	β-strand,	is	also	a	resistance	mutation	site	supports	this	hypothesis.	The	result	of	this	distal	modulation	is	an	effective	decrease	in	the	size	of	the	active	site.	Because	the	NS3/4A	inhibitors	typically	protrude	beyond	the	dynamic	substrate	envelope	(Ozen,	Sherman	et	al.	2013),	this	shrinking	is	expected	to	impair	inhibitor	binding	more	than	substrate	recognition,	and	contribute	to	drug	resistance.	These	results	are	reminiscent	and	consistent	with	the	“network	hypothesis”	and	the	decrease	in	active	site	size	we	observed	previously	with	HIV-1	protease	(Ragland,	Nalivaika	et	al.	2014).		
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The	V36M	mutation	may	also	interfere	with	the	binding	of	the	cofactor	NS4A,	which	aids	in	the	proper	folding	of	NS3.	Substitution	of	a	valine	with	a	larger	sidechain,	methionine,	alters	the	local	packing.	Since	the	A1	strand	containing	V36	is	in	direct	contact	with	NS4A	in	structure,	a	mutation	in	A1	may	as	well	affect	the	interactions	with	NS4A.	A	hindrance	in	cofactor	binding	would	also	interfere	with	substrate	processing	efficiency,	which	may	be	the	reason	for	the	reduced	base-level	replicative	capacity	of	V36M	and	R155K/V36M	variants	of	genotype	1b	viruses	in	the	absence	of	drugs	(44%	and	76%	relative	to	wild-type)	(He,	King	et	al.	2008).		The	MD	simulations	here	provided	additional	insights	also	into	the	mechanism	of	resistance	due	to	R155K	mutation,	which	was	previously	revealed	from	crystal	structures	(Romano,	Ali	et	al.	2010,	Romano,	Ali	et	al.	2012).	The	destabilization	of	danoprevir’s	P2	isoindoline	in	the	presence	of	R155K	both	in	the	crystal	structures	and	MD	simulations	is	consistent	with	earlier	simulation	results	of	Pan	et	al	(Pan,	Xue	et	al.	2012),	indicating	that	the	severe	destabilization	of	P2	is	not	a	crystallization	or	force-field	dependent	artifact.	In	fact,	the	P2	moiety	samples	diverse	conformations	distinct	from	the	one	observed	in	the	crystal	structure	(Figure	3),	with	substantial	losses	in	vdW	interactions	with	the	active	site	protease	residues.		While	the	substrate	envelope	effectively	explains	the	molecular	mechanism	of	resistance	to	most	active	site	mutations,	understanding	the	effect	of	mutations	distal	to	the	binding	site	on	inhibitor	susceptibility	is	more	challenging.	Earlier	studies	on	HIV-1	protease	showed	that	drug	resistance	can	be	conferred	not	only	via	changes	in	direct	interactions	with	the	
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small-molecule	inhibitors	and	substrates	but	also	alterations	in	the	protein	dynamics	(Foulkes-Murzycki,	Scott	et	al.	2007,	Cai,	Yilmaz	et	al.	2012,	Mittal,	Cai	et	al.	2012)	and	propagated	to	the	active	site	(Ragland,	Nalivaika	et	al.	2014).	Mutations	distal	to	the	binding	site	do	not	necessarily	have	an	impact	on	the	native	structure	of	the	protease-inhibitor	complex,	however,	through	changes	in	conformational	dynamics,	the	exchange	rate	between	conformational	states	are	affected.	Consequently,	the	equilibrium	properties	of	inhibitor	binding	are	negatively	impacted.	We	find	that	V36M	is	such	a	distal	mutation,	which	validates	the	network	hypothesis	we	previously	proposed	(Ragland,	Nalivaika	et	al.	2014)	and	allosterically	changes	the	dynamics	at	the	HCV	NS3/4A	protease	active	site	to	aggravate	R155K	resistance.		
Materials	and	Methods		
Mutagenesis	and	gene	information	The	HCV	genotype	1a	NS3/4A	protease	gene,	described	in	a	Bristol-Meyers	Squibb	patent	(Wittekind,	Weinheimer	et	al.	2002),	was	synthesized	by	Gen-Script	and	cloned	into	the	pET28a	expression	vector	(Novagen).	Highly	soluble	NS3/4A	protease	domain	contains	11	core	amino	acids	of	NS4A	covalently	linked	at	the	N	terminus.	A	similar	protease	construct	exhibited	catalytic	activity	comparable	to	that	of	the	authentic	full-length	protein	(Taremi,	Beyer	et	al.	1998).	R155K	and	R155K/V36M	protease	variants	were	generated	using	the	QuikChange	Site-Directed	Mutagenesis	Kit	from	Stratagene	and	sequenced	by	Genewiz.		
Expression	and	purification	
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NS3/4A	protease	expression	and	purification	were	carried	out	as	described	previously	(Gallinari,	Brennan	et	al.	1998,	Wittekind,	Weinheimer	et	al.	2002).	Transformed	Escherichia	coli	BL21(DE3)	cells	were	grown	at	37°C	until	OD600	reached	0.6	and	induced	by	adding	1	mM	IPTG.	Cells	were	harvested	after	overnight	expression	at	4°C	and	pelleted.	Cell	pellets	were	resuspended	in	5	mL/g	of	resuspension	buffer	(50	mM	phosphate	buffer	at	pH	7.5,	500	mM	NaCl,	10%	glycerol,	2	mM	β-mercaptoethanol	[β-ME]),	and	lysed	with	a	cell	disruptor.	The	soluble	fraction	was	applied	to	a	nickel	column	(Qiagen),	washed	with	resuspension	buffer	supplemented	with	20	mM	imidazole,	and	eluted	with	resuspension	buffer	supplemented	with	200	mM	imidazole.	The	eluant	was	dialyzed	overnight	(molecular	mass	cutoff,	10	kDa)	against	resuspension	buffer	to	remove	the	imidazole,	thrombin	treatment	was	applied	simultaneously	to	remove	the	His	tag.	The	nickel-purified	protein	was	then	flash-frozen	with	liquid	nitrogen	and	stored	at	-80°C	for	future	use.		
Crystallization	Danoprevir	was	prepared	in-house	using	our	convergent	reaction	sequence	as	described	previously	(Romano,	Ali	et	al.	2010);		boceprevir	was	provided	by	Merck	&	Co.,	Inc;	telaprevir	was	purchased	from	A	ChemTek,	Inc.	(Worcester,	MA).	For	crystallization,	the	protein	solution	was	thawed	and	loaded	on	a	HiLoad	Superdex75	16/60	column	equilibrated	with	gel	filtration	buffer	(25	mM	morpholineethanesulfonic	acid	[MES]	at	pH	6.5,	500mMNaCl,	10%	glycerol,	30		μM	zinc	chloride,	and	2	mM	dithiothreitol	[DTT]).	The	protease	fractions	were	pooled	and	concentrated	to	25	mg/mL	using	an	Amicon	Ultra-15	10-kDa	device	(Millipore).	The	concentrated	samples	were	incubated	1	h	with	2	to	20	molar	excess	of	protease	inhibitors.	Concentrated	protein	solutions	were	then	mixed	with	
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precipitant	solution	(20	to	26%	polyethylene	glycol	[PEG]	3350,	0.1	M	sodium	MES	buffer	at	pH	6.5,	and	4%	ammonium	sulfate)	at	a	1:1	ratio	in	24-well	VDX	hanging-drop	trays	and	diffraction-quality	crystals	were	obtained	overnight.		
Data	collection	and	structure	solution	Crystals	large	enough	for	data	collection	were	flash-frozen	in	liquid	nitrogen	for	storage.	Constant	cryostream	was	applied	when	mounting	crystal,	and	X-ray	diffraction	data	were	collected	at	Advanced	Photon	Source	LS-CAT	21-ID-F	and	our	in-house	Rigaku_Saturn	944	X-ray	system,	respectively.	The	product	complexes	diffraction	intensities	were	indexed,	integrated,	and	scaled	using	the	program	HKL2000	(Otwinowski	and	Minor	1997).	All	structure	solutions	were	generated	using	simple	isomorphous	molecular	replacement	with	PHASER	(McCoy,	Grosse-Kunstleve	et	al.	2007).	The	model	of	viral	substrate	N-terminal	product	5A-5B	(3M5O)	(Romano,	Ali	et	al.	2010)	was	used	as	the	starting	model	for	all	structure	solutions.	Initial	refinement	was	carried	out	in	the	absence	of	modeled	ligand,	which	was	subsequently	built	in	during	later	stages	of	refinement.	Upon	obtaining	the	correct	molecular	replacement	solutions,	ARP/wARP	or	Phenix	(Adams,	Afonine	et	al.	2010)	were	applied	to	improve	the	phases	by	building	solvent	molecules	(Morris,	Perrakis	et	al.	2002).	Crystallographic	refinement	was	carried	out	within	the	CCP4	program	suite	or	PHENIX	with	iterative	rounds	of	TLS	and	restrained	refinement	until	convergence	was	achieved	(Collaborative-Computational-Project	1994).	The	final	structures	were	evaluated	with	MolProbity	(Davis,	Leaver-Fay	et	al.	2007)	prior	to	deposition	in	the	Protein	Data	Bank.	Five	percent	of	the	data	was	reserved	for	the	free	R-value	calculation	to	prevent	model	bias	throughout	the	refinement	process	(Brunger	1992).	Manual	model	building	and	
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electron	density	viewing	were	carried	out	using	the	program	COOT	(Emsley	and	Cowtan	2004).		
Drug	susceptibility	and	enzyme	inhibition	For	enzyme	inhibition	experiments,	5	nM	of	the	genotype	1a	HCV	NS3/4A	protease	domain	was	incubated	with	increasing	boceprevir	concentrations	for	90	min	in	50	mM	Tris	assay	buffer	(5%	glycerol,	5	mM	TCEP,	6	mM	LDAO	and	4%	DMSO,	pH	7.5).	Proteolysis	reactions	were	initiated	by	adding	100	nM	HCV	NS3/4A	substrate	[Ac-DE-Dap(QXL520)-	EE-Abu-y-[COO]AS-C(5-FAMsp)-NH2]	(AnaSpec)	and	monitored	using	the	EnVision	plate	reader	(Perkin	Elmer)	at	excitation	and	emission	wavelengths	of	485	nm	and	530	nm,	respectively.	The	initial	cleavage	velocities	were	determined	from	sections	of	the	progress	curves	corresponding	to	less	than	15%	substrate	cleavage.	Apparent	inhibition	constants	(Ki)	were	obtained	by	nonlinear	regression	fitting	to	the	Morrison	equation	of	initial	velocity	versus	inhibitor	concentration	using	Prism	5	(GraphPad	Software).	Data	were	collected	in	triplicate	and	processed	independently	to	calculate	the	average	inhibition	constant	and	standard	deviation.		
Distance-difference	maps	The	pair-wise	atomic	distances	between	each	Cα	of	a	given	protease	molecule	and	every	other	Cα	in	the	same	molecule	were	calculated.	The	differences	of	these	Cα-Cα	distances	between	each	pair	of	protease	molecules	were	then	calculated	and	contoured	as	a	map	for	visualization.		These	maps	allow	for	effective	structural	comparisons	without	the	biases	associated	with	superimpositions.		
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Hydrogen	bonds	A	hydrogen	bond	was	defined	based	on	the	criteria	of	donor-acceptor	distance	of	less	than	3.5	Å	and	hydrogen-donor-acceptor	angle	less	than	30º	and	calculated	with	VMD	for	both	MD	trajectories	and	crystal	structures	(Humphrey,	Dalke	et	al.	1996).	However,	the	exact	coordinates	for	hydrogen	atoms,	even	in	structures	of	resolution	as	high	as	1.5	Å,	cannot	be	determined	with	confidence	based	on	the	electron	density	maps.	Therefore,	for	proper	evaluation	of	potential	hydrogen	bonds	in	a	crystal	structure,	hydrogen	atoms	were	added	to	the	crystal	structures	such	that	the	hydrogen	bonding	network	was	optimized	using	Maestro	(Maestro	v9.2.	Portland	2011).	An	energy	minimization	was	also	performed	on	the	crystal	structures	by	completely	constraining	the	non-hydrogen	atoms.	These	structures	were	then	evaluated	for	the	hydrogen	bonds	formed	between	the	protease	and	the	inhibitors.		
Salt	bridges	Salt	bridges	were	defined	as	an	interaction	between	a	side-chain	oxygen	atom	of	Asp	or	Glu	within	4.0	Å	of	a	nitrogen	atom	of	Arg	or	Lys.	The	salt	bridges	in	the	MD	trajectories	were	tracked	using	VMD	(Humphrey,	Dalke	et	al.	1996).		
van	der	Waals	interactions	The	protease-inhibitor	van	der	Waals	contact	energies	were	calculated	by	a	simplified	Lennard-Jones	potential,	as	previously	described	in	detail	(Ozen,	Haliloglu	et	al.	2011).	Using	this	simplified	potential	for	each	nonbonded	protease-inhibitor	pair,	∑V(rij)	was	
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then	computed	for	each	protease	and	inhibitor	residue.	The	Lennard-Jones	parameters,	ε	and	σ,	were	taken	from	the	OPLS2005	forcefield.	For	the	pairs	involving	two	separate	atom	types,	the	parameters	were	geometrically	averaged.		
Molecular	dynamics	simulations	The	crystallographic	waters	within	4.0	Å	of	any	protein	or	inhibitor	atom	were	kept;	all	buffer	salts	were	removed	from	the	coordinate	files.	To	get	a	more	realistic	model	of	the	active	enzyme	interactions	with	the	inhibitors,	the	A139S	back-mutation	was	introduced	in	silico	to	the	crystal	structures	that	originally	have	S139A	mutation	in	the	binding	site	by	deleting	the	Ala	sidechain	and	predicting	the	conformation	of	the	Ser	sidechain	using	the	software	Prime	(Suite	2011:	Prime	3.0	Schrödinger).	Because	the	N-terminal	residues	in	the	NS3/4A	construct,	GSHMASMKKK,	were	extremely	flexible	in	earlier	simulations	and	did	not	form	stable	secondary	structure,	this	region	was	deleted	from	the	coordinate	file	to	reduce	the	computational	cost	(Ozen,	Sherman	et	al.	2013).	The	structures	were	prepared	for	the	MD	simulations	using	the	Protein	Preparation	Wizard	from	Schrödinger	(2011,	Madhavi	Sastry,	Adzhigirey	et	al.	2013).	This	process	adds	hydrogen	atoms,	builds	sidechains	missing	atoms,	and	determines	the	optimal	protonation	states	for	ionizable	sidechains	and	ligand	groups.	In	addition,	the	hydrogen	bonding	network	was	optimized	by	flipping	the	terminal	chi	angle	of	Asn,	Gln,	and	His	residues	and	sampling	hydroxyl/thiol	hydrogens.	The	exhaustive	sampling	option	with	the	inclusion	of	water	orientational	sampling	was	used.	Following	this	step,	the	structure	was	minimized	in	vacuum	with	restraints	on	heavy	atoms	using	he	Impact	Refinement	module	with	the	OPLS2005	force	field	and	terminated	when	the	root-mean	square	deviation	(RMSD)	reached	a	maximum	
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cutoff	of	0.3	Å.	This	step	allows	hydrogen	atoms	to	be	freely	minimized,	while	allowing	heavy-atom	movement	to	relax	strained	bonds,	angles,	and	clashes.			Desmond(Bowers,	Chow	et	al.	2006)	with	OPLS2005	force	field	(Jorgensen,	Chandrasekhar	et	al.	1983,	Shivakumar,	Williams	et	al.	2010)	was	used	in	all	simulations.	The	prepared	systems	were	solvated	in	an	orthorhombic	solvent	box	with	the	SPC	water	model	extending	10	Å	beyond	the	protein	in	all	directions	using	the	System	Builder	utility.	The	overall	charge	of	the	system	was	neutralized	by	adding	the	appropriate	number	of	counterions	(Na+	or	Cl−).			Each	system	was	relaxed	using	a	protocol	consisting	of	an	initial	minimization	restraining	the	solute	heavy	atoms	with	a	force	constant	of	1000	kcal	mol-1	Å-2	for	10	steps	with	steepest	descent	and	with	LBFSG	method	up	to	2000	total	steps	with	a	convergence	criterion	of	50.0	kcal	mol-1	Å-2.	The	system	was	further	minimized	by	restraining	only	the	backbone	and	allowing	the	free	motion	of	the	sidechains.	At	this	stage,	the	restraint	on	the	backbone	was	gradually	reduced	from	1000	to	1.0	kcal	mol-1	Å-2	with	5000	steps	(250	steepest	descent	plus	4750	LBFSG)	for	each	value	of	force	constant	(1000,	500,	250,	100,	50,	10,	1.0	kcal	mol-1	Å-2)	and	finally	an	unrestrained	energy	minimization	was	performed.			After	energy	minimization,	each	system	was	equilibrated	by	running	a	series	of	short	MD	steps.	First,	a	10	ps	MD	simulation	at	10	K	was	performed	with	a	50	kcal	mol-1	Å-2	restraint	on	solute	heavy	atoms	and	using	Berendsen	thermostat	in	the	NVT	ensemble.	MD	steps	were	integrated	using	a	two	time-step	algorithm,	with	1	fs	steps	for	bonded	and	
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short-range	interactions	within	the	9	Å	cutoff	and	3	fs	for	long-range	electrostatic	interactions,	which	were	treated	with	the	smooth	particle-mesh	Ewald	(PME)	method	(Darden,	Darrin	et	al.	1993,	Essmann,	Perera	et	al.	1995).	Time	steps	were	kept	shorter	at	this	first	MD	stage	to	reduce	numerical	issues	associated	with	large	initial	forces	before	the	system	equilibrates.	This	was	followed	by	another	restrained	MD	simulation	for	10	ps	at	10	K	with	a	2	fs	inner	and	6	fs	outer	time	step	in	NPT	ensemble.	The	temperature	of	the	system	was	slowly	increased	from	10	K	to	300	K	over	50	ps	retaining	the	restraint	on	the	system	and	10	ps	MD	was	performed	without	the	harmonic	restraints.	Production	MD	simulations	were	carried	out	at	300	K	and	1	bar	for	100	ns	using	the	NPT	ensemble,	Nose-Hoover	thermostat,	and	Martyna-Tuckerman-Klein	barostat.	The	long-range	electrostatic	interactions	were	computed	using	a	smooth	particle	mesh	Ewald	(PME)	(Essmann,	Perera	et	al.	1995)	approximation	with	a	cutoff	radius	of	9	Å	for	the	transition	between	the	particle-particle	and	particle-grid	calculations	and	van	der	Waals	(vdW)	interactions	were	truncated	at	9	Å.	The	coordinates	and	energies	were	recorded	every	5	ps.			
Molecular	Modeling	Crystal	structures	for	apo	R155K	and	R155K/V36M	variants	were	not	available.	These	structures	were	modeled	using	two	separate	templates.	First,	the	inhibitor	coordinates	were	removed	from	the	crystal	structures	of	the	danoprevir-bound	R155K	(PDB	ID:	3SU0)	and	R155K/V36M	variants	and	the	resulting	structure	were	relaxed	using	the	energy	minimization	protocol	described	above.	Second,	the	mutations	were	introduced	to	the	crystal	structure	of	the	wild-type	apo	protease	and	the	resulting	structures	were	again	minimized	with	the	same	protocol.	To	ensure	the	equivalence	of	the	independently	
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obtained	structural	models,	the	energy-minimized	structures	were	then	compared	with	respect	to	backbone	structural	changes,	side	chain	orientations	of	the	mutated	amino	acids	and	the	spatial	neighbors	of	the	mutation	sites.							
Acknowledgements	This	work	was	supported	by	the	National	Institute	of	Allergy	and	Infectious	Disease	(R01-AI085051	and	2R01AI085051-06).	We	thank	Nese	Kurt	Yilmaz	for	editorial	assistance.		
	 	
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/452284doi: bioRxiv preprint first posted online Nov. 5, 2018; 
	 30	
References	
	Adams,	P.	D.,	P.	V.	Afonine,	G.	Bunkoczi,	V.	B.	Chen,	I.	W.	Davis,	N.	Echols,	J.	J.	Headd,	L.	W.	Hung,	G.	J.	Kapral,	R.	W.	Grosse-Kunstleve,	A.	J.	McCoy,	N.	W.	Moriarty,	R.	Oeffner,	R.	J.	Read,	D.	C.	Richardson,	J.	S.	Richardson,	T.	C.	Terwilliger	and	P.	H.	Zwart	(2010).	"PHENIX:	a	comprehensive	Python-based	system	for	macromolecular	structure	solution."	Acta	Crystallogr	D	Biol	Crystallogr	66(Pt	2):	213-221.	Ali,	A.,	C.	Aydin,	R.	Gildemeister,	K.	P.	Romano,	H.	Cao,	A.	Ozen,	D.	Soumana,	A.	Newton,	C.	J.	Petropoulos,	W.	Huang	and	C.	A.	Schiffer	(2013).	"Evaluating	the	Role	of	Macrocycles	in	the	Susceptibility	of	Hepatitis	C	Virus	NS3/4A	Protease	Inhibitors	to	Drug	Resistance."	ACS	Chem	Biol.	Aydin,	C.,	S.	Mukherjee,	A.	M.	Hanson,	D.	N.	Frick	and	C.	A.	Schiffer	(2013).	"The	interdomain	interface	in	bifunctional	enzyme	protein	3/4A	(NS3/4A)	regulates	protease	and	helicase	activities."	Protein	Sci	22(12):	1786-1798.	Beran,	R.	K.,	B.	D.	Lindenbach	and	A.	M.	Pyle	(2009).	"The	NS4A	protein	of	hepatitis	C	virus	promotes	RNA-coupled	ATP	hydrolysis	by	the	NS3	helicase."	J	Virol	83(7):	3268-3275.	Beran,	R.	K.	and	A.	M.	Pyle	(2008).	"Hepatitis	C	viral	NS3-4A	protease	activity	is	enhanced	by	the	NS3	helicase."	J	Biol	Chem	283(44):	29929-29937.	Bowers,	K.	J.,	E.	Chow,	H.	Xu,	R.	O.	Dror,	M.	P.	Eastwood,	B.	A.	Gregersen,	J.	L.	Klepeis,	I.	Kolossvary,	M.	A.	Moraes,	F.	D.	Sacerdoti,	J.	K.	Salmon,	Y.	Shan	and	D.	E.	Shaw	(2006).	"Scalable	Algorithms	for	Molecular	Dynamics	Simulations	on	Commodity	Clusters."	Proceedings	of	the	ACM/IEEE	Conference	on	Supercomputing	(SC06),	Tampa,	Florida.	Brunger,	A.	T.	(1992).	"Free	R	value:	a	novel	statistical	quantity	for	assessing	the	accuracy	of	crystal	structures."	Nature	355(6359):	472-475.	Cai,	Y.,	N.	K.	Yilmaz,	W.	Myint,	R.	Ishima	and	C.	A.	Schiffer	(2012).	"Differential	Flap	Dynamics	in	Wild-type	and	a	Drug	Resistant	Variant	of	HIV-1	Protease	Revealed	by	Molecular	Dynamics	and	NMR	Relaxation."	J	Chem	Theory	Comput	8(10):	3452-3462.	Collaborative-Computational-Project,	N.	(1994).	"The	CCP4	suite:	programs	for	protein	crystallography."	Acta	Crystallogr	D	Biol	Crystallogr	50:	760-763.	Darden,	T.,	Y.	Darrin	and	L.	Pedersen	(1993).	"Particle	mesh	Ewald:	An	N⋅log(N)	method	for	Ewald	sums	in	large	systems."	Journal	of	Chemical	Physics	98:	10089-10093.	Davis,	I.	W.,	A.	Leaver-Fay,	V.	B.	Chen,	J.	N.	Block,	G.	J.	Kapral,	X.	Wang,	L.	W.	Murray,	W.	B.	Arendall,	3rd,	J.	Snoeyink,	J.	S.	Richardson	and	D.	C.	Richardson	(2007).	"MolProbity:	all-atom	contacts	and	structure	validation	for	proteins	and	nucleic	acids."	Nucleic	Acids	Res	
35(Web	Server	issue):	W375-383.	Emsley,	P.	and	K.	Cowtan	(2004).	"Coot:	model-building	tools	for	molecular	graphics."	Acta	Crystallogr	D	Biol	Crystallogr	60(Pt	12	Pt	1):	2126-2132.	Essmann,	U.,	L.	Perera,	M.	L.	Berkowitz,	T.	Darden,	H.	Lee	and	L.	G.	Pedersen	(1995).	"A	Smooth	Particle	Mesh	Ewald	Method."	Journal	of	Chemical	Physics	103(19):	8577-8593.	Foulkes-Murzycki,	J.	E.,	W.	R.	Scott	and	C.	A.	Schiffer	(2007).	"Hydrophobic	sliding:	a	possible	mechanism	for	drug	resistance	in	human	immunodeficiency	virus	type	1	protease."	Structure	15(2):	225-233.	Frick,	D.	N.,	R.	S.	Rypma,	A.	M.	Lam	and	B.	Gu	(2004).	"The	nonstructural	protein	3	protease/helicase	requires	an	intact	protease	domain	to	unwind	duplex	RNA	efficiently."	J	Biol	Chem	279(2):	1269-1280.	
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/452284doi: bioRxiv preprint first posted online Nov. 5, 2018; 
	 31	
Gallinari,	P.,	D.	Brennan,	C.	Nardi,	M.	Brunetti,	L.	Tomei,	C.	Steinkuhler	and	R.	De	Francesco	(1998).	"Multiple	enzymatic	activities	associated	with	recombinant	NS3	protein	of	hepatitis	C	virus."	J	Virol	72(8):	6758-6769.	Gane,	E.	J.,	P.	Pockros,	S.	Zeuzem,	P.	Marcellin,	A.	Shikhman,	C.	Bernaards,	E.	Yetzer,	N.	S.	Shulman,	X.	Tong,	I.	Najera,	A.	Bertasso,	J.	Hammond	and	S.	Stancic	(2012).	Interferon-Free	Treatment	With	A	Combination	Of	Mericitabine	And	Danoprevir/R	With	Or	Without	Ribavirin	In	Treatment-Naive	Hcv	Genotype	1-Infected	Patients.	63rd	Annual	Meeting	of	the	American	Association	for	the	Study	of	Liver	Diseases.	Halfon,	P.	and	S.	Locarnini	(2011).	"Hepatitis	C	virus	resistance	to	protease	inhibitors."	J	Hepatol	55(1):	192-206.	Halfon,	P.	and	C.	Sarrazin	(2012).	"Future	treatment	of	chronic	hepatitis	C	with	direct	acting	antivirals:	is	resistance	important?"	Liver	Int	32	Suppl	1:	79-87.	He,	Y.,	M.	S.	King,	D.	J.	Kempf,	L.	Lu,	H.	B.	Lim,	P.	Krishnan,	W.	Kati,	T.	Middleton	and	A.	Molla	(2008).	"Relative	replication	capacity	and	selective	advantage	profiles	of	protease	inhibitor-resistant	hepatitis	C	virus	(HCV)	NS3	protease	mutants	in	the	HCV	genotype	1b	replicon	system."	Antimicrob	Agents	Chemother	52(3):	1101-1110.	Howe,	A.	Y.,	J.	Long,	D.	Nickle,	R.	Barnard,	S.	Thompson,	J.	Howe,	K.	Alves	and	J.	Wahl	(2015).	"Long-term	follow-up	of	patients	receiving	boceprevir	for	treatment	of	chronic	hepatitis	C."	Antiviral	Res	113:	71-78.	Humphrey,	W.,	A.	Dalke	and	K.	Schulten	(1996).	"VMD:	visual	molecular	dynamics."	J	Mol	Graph	14(1):	33-38,	27-38.	Jacobson,	I.	M.,	J.	G.	McHutchison,	G.	Dusheiko,	A.	M.	Di	Bisceglie,	K.	R.	Reddy,	N.	H.	Bzowej,	P.	Marcellin,	A.	J.	Muir,	P.	Ferenci,	R.	Flisiak,	J.	George,	M.	Rizzetto,	D.	Shouval,	R.	Sola,	R.	A.	Terg,	E.	M.	Yoshida,	N.	Adda,	L.	Bengtsson,	A.	J.	Sankoh,	T.	L.	Kieffer,	S.	George,	R.	S.	Kauffman	and	S.	Zeuzem	(2011).	"Telaprevir	for	previously	untreated	chronic	hepatitis	C	virus	infection."	N	Engl	J	Med	364(25):	2405-2416.	Jorgensen,	W.	L.,	J.	Chandrasekhar,	J.	D.	Madura,	R.	W.	Impey	and	M.	L.	Klein	(1983).	"Comparison	of	simple	potential	functions	for	simulating	liquid	water."	Journal	of	Chemical	Physics	79:	926-935.	Kieffer,	T.	L.,	C.	Sarrazin,	J.	S.	Miller,	M.	W.	Welker,	N.	Forestier,	H.	W.	Reesink,	A.	D.	Kwong	and	S.	Zeuzem	(2007).	"Telaprevir	and	pegylated	interferon-alpha-2a	inhibit	wild-type	and	resistant	genotype	1	hepatitis	C	virus	replication	in	patients."	Hepatology	46(3):	631-639.	Kwong,	A.	D.,	R.	S.	Kauffman,	P.	Hurter	and	P.	Mueller	(2011).	"Discovery	and	development	of	telaprevir:	an	NS3-4A	protease	inhibitor	for	treating	genotype	1	chronic	hepatitis	C	virus."	Nat	Biotechnol	29(11):	993-1003.	Lim,	S.	R.,	X.	Qin,	S.	Susser,	J.	B.	Nicholas,	C.	Lange,	E.	Herrmann,	J.	Hong,	A.	Arfsten,	L.	Hooi,	W.	Bradford,	I.	Najera,	P.	Smith,	S.	Zeuzem,	K.	Kossen,	C.	Sarrazin	and	S.	D.	Seiwert	(2012).	"Virologic	escape	during	danoprevir	(ITMN-191/RG7227)	monotherapy	is	hepatitis	C	virus	subtype	dependent	and	associated	with	R155K	substitution."	Antimicrob	Agents	Chemother	56(1):	271-279.	Madhavi	Sastry,	G.,	M.	Adzhigirey,	T.	Day,	R.	Annabhimoju	and	W.	Sherman	(2013).	"Protein	and	ligand	preparation:	parameters,	protocols,	and	influence	on	virtual	screening	enrichments."	J	Comput	Aided	Mol	Des.	Maestro	v9.2.	Portland,	O.	S.,	Inc.	(2011).	Malcolm,	B.	A.,	R.	Liu,	F.	Lahser,	S.	Agrawal,	B.	Belanger,	N.	Butkiewicz,	R.	Chase,	F.	Gheyas,	A.	Hart,	D.	Hesk,	P.	Ingravallo,	C.	Jiang,	R.	Kong,	J.	Lu,	J.	Pichardo,	A.	Prongay,	A.	Skelton,	X.	
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/452284doi: bioRxiv preprint first posted online Nov. 5, 2018; 
	 32	
Tong,	S.	Venkatraman,	E.	Xia,	V.	Girijavallabhan	and	F.	G.	Njoroge	(2006).	"SCH	503034,	a	mechanism-based	inhibitor	of	hepatitis	C	virus	NS3	protease,	suppresses	polyprotein	maturation	and	enhances	the	antiviral	activity	of	alpha	interferon	in	replicon	cells."	Antimicrob	Agents	Chemother	50(3):	1013-1020.	Manns,	M.,	H.	Reesink,	T.	Berg,	G.	Dusheiko,	R.	Flisiak,	P.	Marcellin,	C.	Moreno,	O.	Lenz,	P.	Meyvisch,	M.	Peeters,	V.	Sekar,	K.	Simmen	and	R.	Verloes	(2011).	"Rapid	viral	response	of	once-daily	TMC435	plus	pegylated	interferon/ribavirin	in	hepatitis	C	genotype-1	patients:	a	randomized	trial."	Antivir	Ther	16(7):	1021-1033.	Manns,	M.	P.,	M.	Bourliere,	Y.	Benhamou,	S.	Pol,	M.	Bonacini,	C.	Trepo,	D.	Wright,	T.	Berg,	J.	L.	Calleja,	P.	W.	White,	J.	O.	Stern,	G.	Steinmann,	C.	L.	Yong,	G.	Kukolj,	J.	Scherer	and	W.	O.	Boecher	(2011).	"Potency,	safety,	and	pharmacokinetics	of	the	NS3/4A	protease	inhibitor	BI201335	in	patients	with	chronic	HCV	genotype-1	infection."	J	Hepatol	54(6):	1114-1122.	McCoy,	A.	J.,	R.	W.	Grosse-Kunstleve,	P.	D.	Adams,	M.	D.	Winn,	L.	C.	Storoni	and	R.	J.	Read	(2007).	"Phaser	crystallographic	software."	J	Appl	Crystallogr	40(Pt	4):	658-674.	Mittal,	S.,	Y.	Cai,	M.	N.	Nalam,	D.	N.	Bolon	and	C.	A.	Schiffer	(2012).	"Hydrophobic	core	flexibility	modulates	enzyme	activity	in	HIV-1	protease."	J	Am	Chem	Soc	134(9):	4163-4168.	Morris,	R.	J.,	A.	Perrakis	and	V.	S.	Lamzin	(2002).	"ARP/wARP's	model-building	algorithms.	I.	The	main	chain."	Acta	Crystallogr	D	Biol	Crystallogr	D58:	968-975.	Otwinowski,	Z.	and	W.	Minor	(1997).	"Processing	of	X-ray	diffraction	data	collected	in	oscillation	mode."	Methods	Enzymol	276:	307-326.	Ozen,	A.,	T.	Haliloglu	and	C.	A.	Schiffer	(2011).	"Dynamics	of	preferential	substrate	recognition	in	HIV-1	protease:	redefining	the	substrate	envelope."	J	Mol	Biol	410(4):	726-744.	Ozen,	A.,	W.	Sherman	and	C.	A.	Schiffer	(2013).	"Improving	the	Resistance	Profile	of	Hepatitis	C	NS3/4A	Inhibitors:	Dynamic	Substrate	Envelope	Guided	Design."	J	Chem	Theory	Comput	9(12):	5693-5705.	Pan,	D.,	W.	Xue,	W.	Zhang,	H.	Liu	and	X.	Yao	(2012).	"Understanding	the	drug	resistance	mechanism	of	hepatitis	C	virus	NS3/4A	to	ITMN-191	due	to	R155K,	A156V,	D168A/E	mutations:	a	computational	study."	Biochim	Biophys	Acta	1820(10):	1526-1534.	Perni,	R.	B.,	S.	J.	Almquist,	R.	A.	Byrn,	G.	Chandorkar,	P.	R.	Chaturvedi,	L.	F.	Courtney,	C.	J.	Decker,	K.	Dinehart,	C.	A.	Gates,	S.	L.	Harbeson,	A.	Heiser,	G.	Kalkeri,	E.	Kolaczkowski,	K.	Lin,	Y.	P.	Luong,	B.	G.	Rao,	W.	P.	Taylor,	J.	A.	Thomson,	R.	D.	Tung,	Y.	Wei,	A.	D.	Kwong	and	C.	Lin	(2006).	"Preclinical	profile	of	VX-950,	a	potent,	selective,	and	orally	bioavailable	inhibitor	of	hepatitis	C	virus	NS3-4A	serine	protease."	Antimicrob	Agents	Chemother	50(3):	899-909.	Poordad,	F.,	J.	McCone,	Jr.,	B.	R.	Bacon,	S.	Bruno,	M.	P.	Manns,	M.	S.	Sulkowski,	I.	M.	Jacobson,	K.	R.	Reddy,	Z.	D.	Goodman,	N.	Boparai,	M.	J.	DiNubile,	V.	Sniukiene,	C.	A.	Brass,	J.	K.	Albrecht	and	J.	P.	Bronowicki	(2011).	"Boceprevir	for	untreated	chronic	HCV	genotype	1	infection."	N	Engl	J	Med	364(13):	1195-1206.	Raboisson,	P.,	H.	de	Kock,	A.	Rosenquist,	M.	Nilsson,	L.	Salvador-Oden,	T.	I.	Lin,	N.	Roue,	V.	Ivanov,	H.	Wahling,	K.	Wickstrom,	E.	Hamelink,	M.	Edlund,	L.	Vrang,	S.	Vendeville,	W.	Van	de	Vreken,	D.	McGowan,	A.	Tahri,	L.	Hu,	C.	Boutton,	O.	Lenz,	F.	Delouvroy,	G.	Pille,	D.	Surleraux,	P.	Wigerinck,	B.	Samuelsson	and	K.	Simmen	(2008).	"Structure-activity	relationship	study	on	a	novel	series	of	cyclopentane-containing	macrocyclic	inhibitors	of	the	hepatitis	C	virus	
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/452284doi: bioRxiv preprint first posted online Nov. 5, 2018; 
	 33	
NS3/4A	protease	leading	to	the	discovery	of	TMC435350."	Bioorg	Med	Chem	Lett	18(17):	4853-4858.	Ragland,	D.	A.,	E.	A.	Nalivaika,	M.	N.	Nalam,	K.	L.	Prachanronarong,	H.	Cao,	R.	M.	Bandaranayake,	Y.	Cai,	N.	Kurt-Yilmaz	and	C.	A.	Schiffer	(2014).	"Drug	resistance	conferred	by	mutations	outside	the	active	site	through	alterations	in	the	dynamic	and	structural	ensemble	of	HIV-1	protease."	J.	Am.	Chem.	Soc.	136(34):	11956-11963.	Romano,	K.	P.,	A.	Ali,	C.	Aydin,	D.	Soumana,	A.	Ozen,	L.	M.	Deveau,	C.	Silver,	H.	Cao,	A.	Newton,	C.	J.	Petropoulos,	W.	Huang	and	C.	A.	Schiffer	(2012).	"The	molecular	basis	of	drug	resistance	against	hepatitis	C	virus	NS3/4A	protease	inhibitors."	PLoS	Pathog	8(7):	e1002832.	Romano,	K.	P.,	A.	Ali,	W.	E.	Royer	and	C.	A.	Schiffer	(2010).	"Drug	resistance	against	HCV	NS3/4A	inhibitors	is	defined	by	the	balance	of	substrate	recognition	versus	inhibitor	binding."	Proc	Natl	Acad	Sci	U	S	A	107(49):	20986-20991.	Romano,	K.	P.,	J.	M.	Laine,	L.	M.	Deveau,	H.	Cao,	F.	Massi	and	C.	A.	Schiffer	(2011).	"Molecular	mechanisms	of	viral	and	host	cell	substrate	recognition	by	hepatitis	C	virus	NS3/4A	protease."	J	Virol	85(13):	6106-6116.	Rosenquist,	A.,	B.	Samuelsson,	P.	O.	Johansson,	M.	D.	Cummings,	O.	Lenz,	P.	Raboisson,	K.	Simmen,	S.	Vendeville,	H.	de	Kock,	M.	Nilsson,	A.	Horvath,	R.	Kalmeijer,	G.	de	la	Rosa	and	M.	Beumont-Mauviel	(2014).	"Discovery	and	development	of	simeprevir	(TMC435),	a	HCV	NS3/4A	protease	inhibitor."	J	Med	Chem	57(5):	1673-1693.	Sarrazin,	C.,	T.	L.	Kieffer,	D.	Bartels,	B.	Hanzelka,	U.	Muh,	M.	Welker,	D.	Wincheringer,	Y.	Zhou,	H.	M.	Chu,	C.	Lin,	C.	Weegink,	H.	Reesink,	S.	Zeuzem	and	A.	D.	Kwong	(2007).	"Dynamic	hepatitis	C	virus	genotypic	and	phenotypic	changes	in	patients	treated	with	the	protease	inhibitor	telaprevir."	Gastroenterology	132(5):	1767-1777.	Sherman,	K.	E.,	S.	L.	Flamm,	N.	H.	Afdhal,	D.	R.	Nelson,	M.	S.	Sulkowski,	G.	T.	Everson,	M.	W.	Fried,	M.	Adler,	H.	W.	Reesink,	M.	Martin,	A.	J.	Sankoh,	N.	Adda,	R.	S.	Kauffman,	S.	George,	C.	I.	Wright	and	F.	Poordad	(2011).	"Response-guided	telaprevir	combination	treatment	for	hepatitis	C	virus	infection."	N	Engl	J	Med	365(11):	1014-1024.	Shivakumar,	D.,	J.	Williams,	Y.	Wu,	W.	Damm,	J.	Shelley	and	W.	Sherman	(2010).	"Prediction	of	Absolute	Solvation	Free	Energies	using	Molecular	Dynamics	Free	Energy	Perturbation	and	the	OPLS	Force	Field."	J.	Chem.	Theory	Comput.	6:	1509-1519.	Sorbo,	M.,	V.	Cento,	V.	Di	Maio,	A.	Howe,	F.	Garcia,	C.	Perno	and	F.	Ceccherini-Silberstein	(2018).	"Hepatitis	C	virus	drug	resistance	associated	substitutions	and	their	clinical	relevance:	Update	2018."	Drug	Resistance	Updates	37:	17-39.	Soumana,	D.	I.,	A.	Ali	and	C.	A.	Schiffer	(2014).	"Structural	analysis	of	asunaprevir	resistance	in	HCV	NS3/4A	protease."	ACS	Chem	Biol	9(11):	2485-2490.	Suite	2011:	Prime	3.0	Schrödinger,	L.,	New	York,	NY,	2011.	Susser,	S.,	C.	Welsch,	Y.	Wang,	M.	Zettler,	F.	S.	Domingues,	U.	Karey,	E.	Hughes,	R.	Ralston,	X.	Tong,	E.	Herrmann,	S.	Zeuzem	and	C.	Sarrazin	(2009).	"Characterization	of	resistance	to	the	protease	inhibitor	boceprevir	in	hepatitis	C	virus-infected	patients."	Hepatology	50(6):	1709-1718.	Svarovskaia,	E.	S.,	R.	Martin,	J.	G.	McHutchison,	M.	D.	Miller	and	H.	Mo	(2012).	"Abundant	drug-resistant	NS3	mutants	detected	by	deep	sequencing	in	hepatitis	C	virus-infected	patients	undergoing	NS3	protease	inhibitor	monotherapy."	J	Clin	Microbiol	50(10):	3267-3274.	
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/452284doi: bioRxiv preprint first posted online Nov. 5, 2018; 
	 34	
Taremi,	S.	S.,	B.	Beyer,	M.	Maher,	N.	Yao,	W.	Prosise,	P.	C.	Weber	and	B.	A.	Malcolm	(1998).	"Construction,	expression,	and	characterization	of	a	novel	fully	activated	recombinant	single-chain	hepatitis	C	virus	protease."	Protein	Sci	7(10):	2143-2149.	Vermehren,	J.	and	C.	Sarrazin	(2012).	"The	role	of	resistance	in	HCV	treatment."	Best	Pract	Res	Clin	Gastroenterol	26(4):	487-503.	Welsch,	C.,	F.	S.	Domingues,	S.	Susser,	I.	Antes,	C.	Hartmann,	G.	Mayr,	A.	Schlicker,	C.	Sarrazin,	M.	Albrecht,	S.	Zeuzem	and	T.	Lengauer	(2008).	"Molecular	basis	of	telaprevir	resistance	due	to	V36	and	T54	mutations	in	the	NS3-4A	protease	of	the	hepatitis	C	virus."	Genome	Biol	9(1):	R16.	Welsch,	C.	and	S.	Zeuzem	(2012).	"Clinical	relevance	of	HCV	antiviral	drug	resistance."	Curr	Opin	Virol.	Wittekind,	M.	S.,	S.	Weinheimer,	Y.	Zhang	and	V.	Goldfarb	(2002).	Modified	forms	of	hepatitis	C	NS3	protease	for	facilitating	inhibitor	screening	and	structural	studies	of	protease:inhibitor	complexes.	U.S.	patent	6,	186.	Yao,	N.,	P.	Reichert,	S.	S.	Taremi,	W.	W.	Prosise	and	P.	C.	Weber	(1999).	"Molecular	views	of	viral	polyprotein	processing	revealed	by	the	crystal	structure	of	the	hepatitis	C	virus	bifunctional	protease-helicase."	Structure	7(11):	1353-1363.	Yildiz,	M.,	S.	Ghosh,	J.	A.	Bell,	W.	Sherman	and	J.	A.	Hardy	(2013).	"Allosteric	inhibition	of	the	NS2B-NS3	protease	from	dengue	virus."	ACS	Chem	Biol	8(12):	2744-2752.	Zhu,	H.	and	J.	M.	Briggs	(2011).	"Mechanistic	role	of	NS4A	and	substrate	in	the	activation	of	HCV	NS3	protease."	Proteins	79(8):	2428-2443.			 	
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/452284doi: bioRxiv preprint first posted online Nov. 5, 2018; 
	 35	
	
Figure	1.		(A)	Structure	of	HCV	NS3/4A	protease	where	α-helices,	strands,	and	loops	are	colored	in	red,	yellow,	and	green,	respectively.	Side	chains	of	the	catalytic	triad	are	in	magenta	and	the	mutation	sites	R155K	and	V36	are	in	cyan.	(B)	Crystallographic	binding	modes	of	telaprevir,	boceprevir,	and	danoprevir	in	the	wild-type,	R155K	and	R155K/V36M	protease	complexes.	Protease	and	inhibitors	are	represented	as	surface	and	sticks,	respectively.	Side	chains	of	key	residues	are	also	shown	as	sticks;	the	drug	resistance	mutation	sites	R155K	and	V36M	(cyan),	the	catalytic	triad	H57-D81-S139	(magenta),	and	other	binding	site	residues	(green).	Inhibitors	in	complex	with	wild-type,	R155K	and	R155K/V36M	proteases	are	shown	in	blue,	orange	and	yellow	respectively.	
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Figure	2.		Conformational	flexibility	of	danoprevir’s	P2	moiety	is	enhanced	by	the	molecular	interactions	destabilized	due	to	R155K	mutation.	(A)	Crystal	structures	and	(B)	representative	snapshots	from	MD	simulations	with	equal	intervals	of	6	ns	superimposed	on	the	C2,	N2,	C4,	N5,	C11,	and	C15	atoms	of	danoprevir.						
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Figure	3.		Changes	in	the	van	der	Waals	interactions	of	R155K	and	R155K/V36M	protease	residues	relative	to	the	wild-type	protease	for	the	complexes	of	(A)	telaprevir,	(B)	boceprevir,	(C)	danoprevir	from	MD	simulations.	
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Figure	4.		Changes	in	van	der	Waals	interactions	of	(A)	telaprevir,	(B)	boceprevir,	and	(C)	danoprevir	chemical	moieties	with	the	R155K	and	R155K/V36M	proteases	from	MD	simulations	relative	to	the	wild-type	protease.			 	
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Figure	5.		Protease-inhibitor	hydrogen	bonds	in	co-crystal	structures.	(A)	Telaprevir,	(B)	boceprevir,	(C)	danoprevir.	Hydrogen	bonds	are	preserved	in	complexes	of	resistant	variants;	thus	they	are	shown	only	in	wild-type	structures.	See	Table	S2	for	the	resistant	variants.						
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Figure	6.		Distance-difference	maps	showing	the	backbone	perturbations	in	mutant	crystal	structures.	The	core	of	the	protease	is	relatively	unchanged	(colored	blue	on	structure)	
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while	backbone	structural	changes	occur	mostly	around	the	binding	site	and	in	the	loop	regions.		
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Figure	7.		The	backbone	flexibility	of	wild-type	HCV	NS3/4A	protease	during	MD	simulations.	(A)	RMSF	values	for	the	protease	in	the	apo	form	(gray)	and	in	complex	with	telaprevir	(blue),	boceprevir	(red),	and	danoprevir	(green).	(B)	The	RMSF	values	for	the	apo	and	danoprevir-bound	protease	are	mapped	onto	the	respective	crystal	structures.	(C)	The	α2	helix	(130-137),	which	is	conformationally	stabilized	upon	inhibitor	binding,	is	shown	on	the	crystal	structures.			
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Figure	8.	Protease	backbone	flexibility	assessed	by	atomic	positional	fluctuations	during	MD	simulations	in	(A)	unbound	and	(B)	telaprevir-,	(C)	boceprevir-,	and	(D)	danoprevir-bound	states	of	WT	(blue),	R155K	(red),	R155K/V36M	(green)	proteases.			 	
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Figure	9.	The	dynamic	distance	distribution	between	protease	residue	pairs	sampled	during	MD	simulations.	The	distance	between	(A)	F43	and	the	sites	of	mutation	(V/M36–F43,	F43–R/K155),	and	(B)	the	catalytic	triad	residues	(H57–D81,	H57–S139,	D81–S139).	The	distance	(in	Å)	between	the	Cα	atoms	of	the	two	residues	is	plotted	against	the	percent	time	that	distance	was	observed.		
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Table	1.		Drug	susceptibilities	against	wild-type	and	resistant	HCV	clones	and	inhibitory	activities	against	NS3/4A	proteases.	
Full-length	NS3/4A	Enzyme	-	Ki	(nM)a		 WT	 R155K	 R155K/V36M	
Telaprevir	 40.9	±	3.7	 824.0	±	75.1	(20)	 >10,000	(>244)	
Boceprevir	 34.7	±	2.9	 390.8	±	43.0	(11)	 1018.0	±	192.3	(29)	
Danoprevir	 1.2	±	0.1	 132.0	±	18.0	(111)	 292.9	±	38.6	(246)	
Protease	domain	Ki	(nM)a			
	 WT	 R155K	 R155K/V36M	
Telaprevir	 33.3	±	4.0	 803.7	±	89.9	(24)	 7342	±	1281	(220)	
Boceprevir	 35.4	±	3.3	 236.7	±	44.3	(7)	 1097.0	±	120.4	(31)	
Danoprevir	 1.0	±	0.1	 157.9	±	20.5	(158)	 295.5	±	34.3	(295)	
Replicon	IC50	(nM)a			 WT	 R155K	 R155K/V36M	
Telaprevir	 1349	 4740	(3.5)	 15759	(12)	
Boceprevir	 971	 2788	(3)	 3941	(4)	
Danoprevir	 0.24	 >100	(>416)	 >100	(>416)	aNumbers	in	parentheses	reflect	fold-change	relative	to	wild-type;	>	indicates	IC50	and	Ki	values	higher	than	the	maximum	drug	concentration	tested	in	the	assay.		
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Table	2.		Intramolecular	salt	bridges	forming	a	network	at	the	NS3/4A	active	site	surface	in	crystal	structures,	and	stabilities	assessed	by	MD	simulations.	
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